News Focus
News Focus
icon url

WealthBuilder

04/26/10 1:35 AM

#26966 RE: $heff #26962

on the 30th FDA should " EASLY " approve ! looks like he knows what he's talking about .. 4 more days $heff .. really excited .. good luck
icon url

Investor100

04/26/10 10:10 AM

#26982 RE: $heff #26962

Highlights @ POZN

PPS:$11.00

Some highlights @ POZN

1) Company with solid data and p values that are statistically significant in all the endpoints.

2) Company that has Special Protocol Assessments with the FDA on 2 drugs (including Vimovo).

3) Company has always been debt free in 10 years of being a public company.

4) Company has never diluted their shares or gone to the market for financing.

5) The market needs an agent for pain without the GI toxicity. Clinical data shows this company has a plan in place to address this need.

6) Astra Zeneca and Glaxo Smithkline are already partnered with PONZ.

7) The royalty opportunities for POZN are strong:POZN will get $20 million if Vimovo is approved, along with royalty payments on sales.

GLTA

Investor 100
icon url

$heff

04/26/10 11:34 AM

#27002 RE: $heff #26962

POZN ($10.26) looks great this morning. Shook off the slow start this morning and should be running into Thursday & Friday. $heff
icon url

read_this_n0w

04/26/10 12:16 PM

#27008 RE: $heff #26962

CPST 1.22-1.28 is accumulation zone, will run hard coming weeks.months

Nice growth company, good technology.
expect 3-4$ , maybe 2.75 could be higher

Chart getting tight!